Coverage your patients can count on

Xiidra is covered for most patients in the US1

Not an actual patient.

sticky line
Ken Jeong

Not an actual patient.

sticky line

Coverage your patients can count on

Xiidra is covered for most patients in the US1

Xiidra has ~90% OVERALL COVERAGE
for commercial and Medicare Part D patients nationwide1*

Checklist image

COMMERCIAL

Xiidra coverage exceeds Restasis® in most major plans1†

Checklist image

PAY AS LITTLE AS $0

With Xiidra, eligible commercial patients pay $0 for their first Rx2‡

When using the Xiidra Co-pay Card, 90% of eligible commercial patients paid $03‡§

Checklist image

MEDICARE PART D

Xiidra offers equal coverage to Restasis® in most major plans4

PAY AS LITTLE AS $0 for XIIDRAII

BlinkRx works with your eligible commercially insured patients’ insurance and applies available savings to their Xiidra prescription. No co-pay card needed.II

PRIOR AUTHORIZATION SUPPORT

BlinkRx services provide prior authorization support for Xiidra prescriptions, should your patients’ insurance require it.

SIMPLE PATIENT EXPERIENCE

BlinkRx will send patients a text with the lowest available price so that they can immediately purchase their Xiidra prescription online or over the phone.

FREE FAST DELIVERY

BlinkRx delivers Xiidra prescriptions for free from one of their licensed network pharmacies around the country.

AMPLE STOCKING

BlinkRx services the entire country, making Xiidra accessible for all patients.

DEDICATED CUSTOMER SUPPORT

BlinkRx has a team of pharmacists and technicians that are available to support you, your team, and your patients from onboarding to adherence.

BlinkRx provides support for both commercial and Medicare Part D patients

Eligible commercially insured patients may pay as little as a $0 co-pay.3II

How it works

BlinkRx is an option that can help patients save time and money on their Xiidra prescriptions.

Checklist image, contact image, delivery image Checklist image, contact image, delivery image

Prescribe Xiidra through your EHR to BlinkRx U.S. in Boise, Idaho,
or contact BlinkRx by phone at 1-833-914-3856 or fax at 1-866-585-4631.

||Co-pay offers are also available outside of the BlinkRx program.

Download these resources for use in your practice

Xiidra Patient Profiles

patient profile image

Xiidra Patient Profiles

These 3 profiles represent patient types you may see in practice. They can help you evaluate whether Xiidra may be an appropriate treatment option.

DOWNLOAD

Xiidra Prior Authorization Checklist

prior authorization checklist image

Xiidra Prior Authorization Checklist

Ensure seamless access assistance for appropriate patients with this easy-to-use Prior Authorization Checklist.

DOWNLOAD

BlinkRx Guide

blink rx guide image

BlinkRx Guide

Download these step-by-step instructions on filling a prescription through BlinkRx.

DOWNLOAD

BlinkRx Commercial Patient Quick Guide

commercial patient quick guide image

BlinkRx Commercial Patient Quick Guide

This is a resource for commercial patients about the BlinkRx program.

DOWNLOAD

BlinkRx Fax Form

blink rx fax form image

BlinkRx Fax Form

This form is used to e-prescribe Xiidra through BlinkRx. For more details, see the BlinkRx information above.

DOWNLOAD

BlinkRx Patient (Government Insured) Quick Guide

government insured quick guide image

BlinkRx Patient (Government Insured) Quick Guide

This resource for government-insured patients (including Medicare Part D) provides details on the BlinkRx program.

DOWNLOAD

BlinkRx EHR Flashcard

blink rx EHR flashcard image

BlinkRx EHR Flashcard

This flashcard provides information on how to find BlinkRx in your EHR.

DOWNLOAD
eye icon

Xiidra patient
resources

Help your patients learn more about Xiidra and the relief it can offer for their dry eye symptoms.

 EHR, electronic health record.

*Based on data from February 2024. Up to 95% of commercial patients and 71% of Medicare Part D patients may be covered.

Plan limitations may apply.

Terms and conditions apply. For the first 30-day, 60-day, or 90-day prescription. Subject to benefit limitations. Visit Xiidra.com for complete terms and conditions.

§From data on file: Average payments between January 1 and December 6 of 2023, ConnectiveRx data.

Indication

Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).

Important Safety Information

  • Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
  • In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.
  • To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.
  • Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.
  • Safety and efficacy in pediatric patients below the age of 17 years have not been established.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Click here for Full Prescribing Information.

INDICATION AND IMPORTANT SAFETY INFORMATION

Indication

Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).

Important Safety Information

  • Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
  • In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.
  • To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.
  • Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.
  • Safety and efficacy in pediatric patients below the age of 17 years have not been established.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Click here for Full Prescribing Information.